The FDA determined that a third shot can help boost protection for children in this age group and the benefits outweigh the risks.
Highlights
- Pfizer’s Covid vaccine for children ages 5 to 11 at least five months after their two-dose primary series.
- CDC has final say on whether health-care providers should start administering the boosters.
- The FDA determined that a third shot can help boost protection for children in this age group and the benefits outweigh the risks, the FDA says.
- The drug regulator did not identify any new safety concerns and found the children experienced the same mild side effects that other people do after receiving a booster dose.
- The U.S.
- reported more than 90,000 new infections a day on average as of Sunday, a 30% increase over the week prior.